Biosyent (TSXV:RX) E10: C$0.52 (As of Mar. 2026)


TSXV:RX Biosyent Inc TSXV:RX
100 GF Score
Price C$14.69
GF Value C$16.11
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Biosyent E10?

Biosyent TSXV:RX +4.56% 100 E10 is C$0.52 as of Mar. 2026. GuruFocus rates TSXV:RX with a GF Score™ of 100/100 and a GF Value™ of C$16.11 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biosyent's adjusted earnings per share data for the three months ended in Mar. 2026 was C$0.202. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is C$0.52 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biosyent's average E10 Growth Rate was 10.60% per year. During the past 3 years, the average E10 Growth Rate was 12.30% per year. During the past 5 years, the average E10 Growth Rate was 13.50% per year. During the past 10 years, the average E10 Growth Rate was 19.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Biosyent was 122.40% per year. The lowest was 12.30% per year. And the median was 16.90% per year.

As of today (2026-06-29), Biosyent's current stock price is C$14.69. Biosyent's E10 for the quarter that ended in Mar. 2026 was C$0.52. Biosyent's Shiller PE Ratio of today is 28.25.

During the past 13 years, the highest Shiller PE Ratio of Biosyent was 98.44. The lowest was 14.64. And the median was 26.76.


Biosyent  (TSXV:RX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biosyent's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=14.69/0.52
=28.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Biosyent was 98.44. The lowest was 14.64. And the median was 26.76.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Biosyent E10 Related Terms


Biosyent E10 Historical Data

* Premium members only.

The historical data trend for Biosyent's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosyent E10 Chart

Biosyent Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.36 0.41 0.45 0.51

Biosyent Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.48 0.49 0.51 0.52

TSXV:RX vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biosyent's Shiller PE Ratio falls into.


TSXV:RX
100GF Score
Biosyent Inc TSXV:RX
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosyent E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biosyent's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.202/132.2623*132.2623
=0.202

Current CPI (Mar. 2026) = 132.2623.

Biosyent Quarterly Data

per share eps CPI Adj_EPS
201606 0.070 102.002 0.091
201609 0.080 101.765 0.104
201612 0.070 101.449 0.091
201703 0.060 102.634 0.077
201706 0.110 103.029 0.141
201709 0.090 103.345 0.115
201712 0.100 103.345 0.128
201803 0.080 105.004 0.101
201806 0.110 105.557 0.138
201809 0.090 105.636 0.113
201812 0.110 105.399 0.138
201903 0.070 106.979 0.087
201906 0.049 107.690 0.060
201909 0.110 107.611 0.135
201912 0.080 107.769 0.098
202003 0.110 107.927 0.135
202006 0.055 108.401 0.067
202009 0.074 108.164 0.090
202012 0.052 108.559 0.063
202103 0.129 110.298 0.155
202106 0.079 111.720 0.094
202109 0.134 112.905 0.157
202112 0.147 113.774 0.171
202203 0.125 117.646 0.141
202206 0.096 120.806 0.105
202209 0.116 120.648 0.127
202212 0.097 120.964 0.106
202303 0.095 122.702 0.102
202306 0.121 124.203 0.129
202309 0.195 125.230 0.206
202312 0.121 125.072 0.128
202403 0.149 126.258 0.156
202406 0.134 127.522 0.139
202409 0.195 127.285 0.203
202412 0.138 127.364 0.143
202503 0.201 129.181 0.206
202506 0.176 129.892 0.179
202509 0.233 130.287 0.237
202512 0.177 130.366 0.180
202603 0.202 132.262 0.202

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of C$0.52 mean?
Biosyent (TSXV:RX) has a E10 of C$0.52 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Biosyent and its competitors.
Is Biosyent's E10 too high?
Biosyent's current E10 is C$0.52. Overall, Biosyent has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's E10 compare to ZTS and UTHR?
Biosyent's E10 of C$0.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Biosyent and its competitors. Biosyent's current E10 is C$0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (TSXV:RX) is currently considered Fairly Valued. The stock's GF Value™ is C$16.11, compared to a current price of C$14.69 — trading 8.8% below its estimated fair value. The current E10 is C$0.52. Biosyent's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Biosyent (TSXV:RX), the current E10 is C$0.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biosyent (TSXV:RX) Overvalued in 2026?

Based on GuruFocus' analysis, Biosyent stock appears to be undervalued. The current stock price of C$14.69 is trading 8.8% below its estimated GF Value™ of C$16.11. GuruFocus considers Biosyent to be Fairly Valued.

Key valuation signals for TSXV:RX:

  • E10: C$0.52
  • GF Value™: C$16.11 vs. price of C$14.69 (8.8% below fair value)
  • GF Score™: 100/100 with 2 warning signs

No single metric tells the full story. See the TSXV:RX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biosyent Business Description

Other Exchanges BIOYF:USA
Address 2476 Argentia Road, Suite 402, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
100GF Score

Get the complete analysis for TSXV:RX

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$14.69
Price
C$16.11
GF Value